150 related articles for article (PubMed ID: 21734411)
21. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Beyer J; Liersch R; Schoeffski P; Metzner B; Hartmann JT; Rick O; Stengele K; Hohloch K; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2004 Jan; 22(1):108-14. PubMed ID: 14701772
[TBL] [Abstract][Full Text] [Related]
22. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
Loehrer PJ; Einhorn LH; Williams SD
J Clin Oncol; 1986 Apr; 4(4):528-36. PubMed ID: 3633952
[TBL] [Abstract][Full Text] [Related]
23. Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Weinknecht S; Schirren J; Pottek T; Hartmann JT; Braun T; Rachud B; Weissbach L; Hartmann M; Siegert W; Beyer J
J Clin Oncol; 2004 Sep; 22(18):3713-9. PubMed ID: 15365067
[TBL] [Abstract][Full Text] [Related]
24. First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
Tanaka H; Yuasa T; Fujii Y; Sakura M; Urakami S; Yamamoto S; Masuda H; Fukui I; Yonese J
Chemotherapy; 2013; 59(6):441-6. PubMed ID: 25060582
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma.
Zustovich F; Lombardi G; Della Puppa A; Rotilio A; Scienza R; Pastorelli D
Anticancer Res; 2009 Oct; 29(10):4275-9. PubMed ID: 19846986
[TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
[TBL] [Abstract][Full Text] [Related]
27. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.
Albany C; Fazal Z; Singh R; Bikorimana E; Adra N; Hanna NH; Einhorn LH; Perkins SM; Sandusky GE; Christensen BC; Keer H; Fang F; Nephew KP; Spinella MJ
Cancer Med; 2021 Jan; 10(1):156-163. PubMed ID: 33135391
[TBL] [Abstract][Full Text] [Related]
28. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.
Oechsle K; Honecker F; Cheng T; Mayer F; Czaykowski P; Winquist E; Wood L; Fenner M; Glaesener S; Hartmann JT; Chi K; Bokemeyer C; Kollmannsberger C
Ann Oncol; 2011 Dec; 22(12):2654-2660. PubMed ID: 21415240
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Chamberlain MC; Johnston SK
Cancer; 2009 Oct; 115(20):4775-82. PubMed ID: 19569246
[TBL] [Abstract][Full Text] [Related]
30. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
31. Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome.
Bokemeyer C; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Einhorn L; Nichols CR; Hartmann JT
Cancer; 2001 Apr; 91(7):1394-401. PubMed ID: 11283942
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
33. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy.
Beyer J; Kingreen D; Krause M; Schleicher J; Schwaner I; Schwella N; Huhn D; Siegert W
Cancer; 1997 Jan; 79(1):161-8. PubMed ID: 8988741
[TBL] [Abstract][Full Text] [Related]
34. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
Subbiah V; Meric-Bernstam F; Mills GB; Shaw KR; Bailey AM; Rao P; Ward JF; Pagliaro LC
J Hematol Oncol; 2014 Aug; 7():52. PubMed ID: 25085632
[TBL] [Abstract][Full Text] [Related]
35. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
36. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial.
Mego M; Svetlovska D; Angelis V D; Kalavska K; Lesko P; Makovník M; Obertova J; Orszaghova Z; Palacka P; Rečková M; Rejlekova K; Z SM; Mardiak J; Chovanec M
Invest New Drugs; 2022 Oct; 40(5):1080-1086. PubMed ID: 35763178
[TBL] [Abstract][Full Text] [Related]
38. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience.
De Giorgi U; Demirer T; Wandt H; Taverna C; Siegert W; Bornhauser M; Kozak T; Papiani G; Ballardini M; Rosti G;
Ann Oncol; 2005 Jan; 16(1):146-51. PubMed ID: 15598952
[TBL] [Abstract][Full Text] [Related]
39. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?
Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y
J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
